久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
您當(dāng)前的位置: 網(wǎng)站首頁 > 產(chǎn)品展廳 >試劑盒 >BioSim Cergutuzumab ELISA Kit(KDC21001)
BioSim Cergutuzumab ELISA Kit(KDC21001)
  • 品牌:AntibodySystem
  • 產(chǎn)地:France
  • 型號:96 assays
  • 貨號:KDC21001
  • 發(fā)布日期: 2022-07-25
  • 更新日期: 2024-10-23
產(chǎn)品詳請
產(chǎn)地 France
保存條件 2-8 ℃
品牌 AntibodySystem
貨號 KDC21001
用途 For Research Use Only.
檢測方法 Elisa
CAS編號
保質(zhì)期 1 year
適應(yīng)物種 Cergutuzumab
檢測限 0.156 ug /ml
數(shù)量 99999
包裝規(guī)格 96 assays
標(biāo)記物 Unconjugate
純度 95%%
樣本 Plasma, Serum
應(yīng)用 Elisa
是否進口


Catalog No.

KDC21001

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Cergutuzumab

Alternative Names

CEA-IL-2v, RG7813, RO-6895882, CAS: 1509916-03-3

Background

cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to (i) avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding; (ii) increase the therapeutic index of IL-2 therapy by (a) preferential retention at the tumor by having a lower dissociation rate from CEA-expressing cancer cells vs. IL-2R-expressing cells, (b) avoiding any FcγR-binding and Fc effector functions and (c) reduced binding to endothelial cells expressing CD25; and (iii) improve the pharmacokinetics, and thus convenience of administration, of IL-2.

Shipping

2-8 ℃

Note

For Research Use Only.


Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.




AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗的 創(chuàng)立于法國,專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)






聯(lián)系方式
手機:18162686757
微信掃一掃
舞钢市| 萝北县| 彭泽县| 汪清县| 华亭县| 浙江省| 巴林右旗| 连江县| 石棉县| 临沂市| 临湘市| 丰都县| 青浦区| 集安市| 三门县| 清丰县| 济宁市| 沁源县| 榆树市| 贵港市| 丰都县| 荔波县| 博罗县| 安多县| 襄樊市| 平山县| 景洪市| 襄汾县| 兴海县| 禹城市| 滁州市| 庆元县| 桐柏县| 囊谦县| 游戏| 蚌埠市| 庆云县| 宁海县| 锡林浩特市| 扶沟县| 金乡县|